Financing ·
Glucotrack, Inc. entered into a securities purchase agreement on September 24, 2026, for a registered direct offering…
GCTKGlucotrack, Inc.
Glucotrack, Inc. entered into a securities purchase agreement on September 24, 2026, for a registered direct offering of 169,388 shares of common stock and pre-funded warrants to purchase up to 1,350,220 additional shares. The shares were priced at $2.04 each, and the pre-funded warrants at $2.039 each, generating approximately $3.1 million in gross proceeds before fees. Dawson James Securities acted as placement agent for a fee of 8.0% of gross proceeds. Proceeds will be used to pay off existing debt, with the remainder allocated to working capital and general corporate purposes. The offering closed on September 25, 2026. Glucotrack operates in the medical device industry, focusing on the design, development, and commercialization of novel technologies for diabetes management, including an implantable continuous blood glucose monitoring system.